ALDX - Aldeyra Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
7.60
+0.15 (+2.03%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.45
Open7.60
Bid5.00 x 200
Ask11.45 x 300
Day's Range7.40 - 7.65
52 Week Range3.80 - 11.90
Volume93,455
Avg. Volume94,538
Market Cap145.295M
Beta1.74
PE Ratio (TTM)N/A
EPS (TTM)-1.40
Earnings DateMar 28, 2018 - Apr 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.29
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

    Poster Presentations to Feature Phase 2b Allergic Conjunctivitis Results, in Addition to Activity of Reproxalap and ADX-103 in Models of Retinal Inflammation, Diabetic Macular Edema, and Dry Age-Related ...

  • GlobeNewswire16 days ago

    New Research Coverage Highlights Carter's, Invacare, Hortonworks, BGC Partners, Hyatt Hotels, and Aldeyra Therapeutics — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carter's, ...

  • PR Newswire26 days ago

    Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2b Clinical Trial

    LEXINGTON, Mass., Jan. 30, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation and inborn errors of metabolism, today announced that it has enrolled the first patient in a Phase 2b clinical trial of topical ocular reproxalap for the treatment of dry eye disease (DED). The Phase 2b clinical trial will test two concentrations of topical reproxalap (0.1% and 0.25%) against vehicle over 12 weeks of treatment in 300 patients with moderate dry eye disease.

  • Why Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) CEO Pay Matters To You
    Simply Wall St.2 months ago

    Why Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) CEO Pay Matters To You

    Leading Aldeyra Therapeutics Inc (NASDAQ:ALDX) as the CEO, Todd Brady took the company to a valuation of USD$126.18M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • PR Newswire3 months ago

    Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data to the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

    LEXINGTON, Mass., Nov. 29, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) ("Aldeyra"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented new statistical analyses of the results of a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase 2 clinical trial of topical ocular reproxalap (formerly known as ADX-102), a first-in-class aldehyde sequestering agent, to the American Uveitis Society held at the American Academy of Ophthalmology 2017 Annual Meeting. The results of the analyses demonstrated formal statistical non-inferiority (p=0.036 after two weeks of therapy, p=0.048 after four weeks of therapy) of 0.5% reproxalap ophthalmic solution to Pred Forte®, a topical ocular corticosteroid, in reducing anterior chamber inflammatory cell count, the standard noninfectious anterior uveitis clinical endpoint.

  • Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?
    Simply Wall St.4 months ago

    Does Aldeyra Therapeutics Inc’s (ALDX) Debt Level Pose A Serious Problem?

    Aldeyra Therapeutics Inc (NASDAQ:ALDX) is a small-cap stock with a market capitalization of USD $113.75M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • PR Newswire4 months ago

    Aldeyra Therapeutics Announces Third Quarter 2017 Financial Results

    LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, ...

  • PR Newswire4 months ago

    Aldeyra Therapeutics to Present at the Stifel 2017 Healthcare Conference

    LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, ...

  • PR Newswire4 months ago

    Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2017 Financial Results

    LEXINGTON, Mass. , Nov. 2, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, ...

  • PR Newswire4 months ago

    Aldeyra Therapeutics Announces Presentation of Results on the Efficacy of ADX-102 in Noninfectious Anterior Uveitis at the American Uveitis Society Held at the American Academy of Ophthalmology 2017 Annual Meeting

    LEXINGTON, Mass., Oct. 25, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will present data from the previously announced Phase 2 clinical trial in noninfectious anterior uveitis (NAU) demonstrating statistical non-inferiority of ADX-102 to corticosteroid (Pred Forte®) monotherapy at the American Uveitis Society Fall Meeting held in conjunction with the American Academy of Ophthalmology 2017 Annual Meeting November 11 - 14 in New Orleans, Louisiana. NAU is a severe inflammatory disease that can cause blindness. NAU is typically treated with corticosteroids, which are often effective but can lead to serious ocular toxicities, including glaucoma and cataracts.

  • PR Newswire4 months ago

    Aldeyra Therapeutics Presents Evidence for Aldehyde Sequestration as a Potential Therapeutic Approach in Succinic Semialdehyde Dehydrogenase Deficiency at the American Society of Human Genetics 2017 Annual Meeting

    LEXINGTON, Mass., Oct. 24, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, presented novel data at the American Society of Human Genetics 2017 Annual Meeting demonstrating that ADX-102 reduced levels of gamma-hydroxybutyrate (GHB) and gamma-aminobutyrate (GABA) in a knockout mouse model of Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency. SSADH Deficiency is an orphan neurological disease caused by mutations in SSADH, resulting in elevated levels of succinic semialdehyde. Excess succinic semialdehyde is converted into GHB, GABA, and other metabolites that lead to severe neurological dysfunction, including cognitive delay, seizures, and motor dysfunction.

  • PR Newswire5 months ago

    Aldeyra Therapeutics Announces New Data at 2017 Research & Development Day

    LEXINGTON, Mass., Oct. 10, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) ("Aldeyra" or "the Company"), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, announced new clinical data for ADX-102 from recently completed Phase 2 clinical trials of dry eye disease and allergic conjunctivitis, and the introduction of a retinal disease development program with ADX-103, a novel aldehyde trap. "These newly released results from our Phase 2 clinical trials in dry eye disease and allergic conjunctivitis strongly support the broad and clinically relevant activity profile of ADX-102 in ocular inflammatory disease," commented Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra.

  • PR Newswire5 months ago

    Aldeyra Therapeutics Announces Presentation of Novel Data on the Efficacy of ADX-102 in a Model of Succinic Semialdehyde Dehydrogenase Activity at the 2017 American Society of Human Genetics Annual Meeting

    LEXINGTON, Mass., Oct. 5, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will present novel data on the efficacy of ADX-102 in a model of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) at the 2017 American Society of Human Genetics Annual Meeting, to be held on October 17 - 21 in Orlando, Florida. SSADHD is a rare inborn error of aldehyde metabolism caused by elevations of succinic semialdehyde, a toxic aldehyde that can lead to severe neurological disability.  By trapping succinic semialdehyde, ADX-102 represents a potential novel approach for the treatment of SSADHD. The novel aldehyde trap ADX-102 reduces accumulations of GHB and GABA in brain tissue from succinic semialdehyde dehydrogenase-deficient mice.

  • Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?
    Simply Wall St.5 months ago

    Aldeyra Therapeutics Inc (ALDX): How Does It Impact Your Portfolio?

    If you are looking to invest in Aldeyra Therapeutics Inc’s (NASDAQ:ALDX), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • PR Newswire5 months ago

    /C O R R E C T I O N -- Aldeyra Therapeutics, Inc./

    In the news release, Aldeyra Therapeutics Announces 2017 Research and Development Day, issued 27-Sep-2017 by Aldeyra Therapeutics, Inc. over PR Newswire, we are advised by the company that the date in the second paragraph should read "Tuesday, October 10, 2017" rather than "Monday, October 10, 2017" as originally issued.

  • PR Newswire5 months ago

    Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

    LEXINGTON, Mass. , Sept. 21, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, ...

  • PR Newswire5 months ago

    Aldeyra Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference

    LEXINGTON, Mass. , Sept. 20, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, ...

  • PR Newswire5 months ago

    Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

    LEXINGTON, Mass., Sept. 19, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced the pricing of an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $7.25 per share. In addition, Aldeyra granted the underwriters a 30-day option to purchase up to 517,500 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The shares of common stock described above are being offered by Aldeyra pursuant to its shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on September 1, 2015.

  • PR Newswire5 months ago

    Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

    LEXINGTON, Mass., Sept. 18, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Aldeyra also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering, at the public offering price, less the underwriting discounts and commissions. The shares of common stock described above are being offered by Aldeyra pursuant to a shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on September 1, 2015.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 15, 2017 / The Dow Jones Industrial Average closed at a new record high for the third consecutive session on the strength of Boeing and United Technologies, while ...

  • Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session
    Zacks5 months ago

    Aldeyra Therapeutics (ALDX) Soars: Stock Adds 34.5% in Session

    Aldeyra Therapeutics (ALDX) saw a big move last session, as its shares jumped more than 34% on the day, amid huge volumes.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Stocks to Watch: Aldeyra Therapeutics and Aethlon Medical

    NEW YORK, NY / ACCESSWIRE / September 13, 2017 / Shares of both Aldeyra Therapeutics and Aethon Medical both saw big gains on Tuesday with trading volume for both stocks exploding. Aldeyra rose higher ...

  • TheStreet.com5 months ago

    Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

    The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept ...